Can Serum ST2 Levels Be Used as a Marker of Fibrosis in Chronic Hepatitis B Infection?

Basit Öğe Kaydı
dc.authoridSuna, Nuretdin/0000-0001-6234-7788|Onder, Fatih Oguz/0000-0003-2845-201X;
dc.contributor.authorOztas, Erkin
dc.contributor.authorKuzu, Ufuk Baris
dc.contributor.authorZengin, Neslihan Inci
dc.contributor.authorKalkan, Ismail Hakki
dc.contributor.authorSaygili, Fatih
dc.contributor.authorOnder, Fatih Oguz
dc.contributor.authorYildiz, Hakan
dc.date.accessioned2025-10-24T18:09:21Z
dc.date.available2025-10-24T18:09:21Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractInterleukin 33 (IL-33) is a cytokine belonging to the IL-1 superfamily. Soluble ST2 (sST2) binds to IL-33 and by functioning as trap receptor inhibits signal sending to Th2 via transmembrane ST2. Because Th2-type cytokines play an important role in fibrosis, the aim of this study is to determine whether sST2 can be used as a marker of fibrosis in chronic hepatitis B (CHB) patients or not.The study included 19 healthy controls, 54 patients with CHB, and 14 patients with cirrhosis because of CHB. The aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis index based on the 4 factors (FIB-4) scores also calculated, and correlations between liver biopsies, sST2 levels, and these scores were analyzed in CHB and cirrhosis patients.The sST2 levels in patients with CHB were significantly higher than those in the control group subjects (median: 1133pg/mL vs 762.5pg/mL, respectively [P=0.035]). In CHB patients, the METAVIR fibrosis score (stages from 0 to 4) showed a moderate correlation with serum sST2 level (r=0.396, P=0.004) and a weak correlation with FIB-4 score (r=0.359, P=0.008), but no correlation with APRI score (r=0.253, P=0.06). The under the curve value of serum sST2 was 0.68, and its prediction of significant fibrosis (METAVIR score 2) in values >674pg/mL had a sensitivity of 91.7% and specificity of 40% (P=0.009). According to multiple logistic regression analysis, only METAVIR fibrosis stage was found to be an independent predictor of serum sST2 elevation in CHB patients (P=0.04).The sST2 level can be used for differentiating significant fibrosis from mild fibrosis in CHB patients. However, the efficacy of this marker should be verified by larger studies in the future.
dc.identifier.doi10.1097/MD.0000000000001889
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.issue47
dc.identifier.pmid26632683
dc.identifier.scopus2-s2.0-84979862460
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1097/MD.0000000000001889
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3578
dc.identifier.volume94
dc.identifier.wosWOS:000369539300007
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofMedicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectPredicting Liver-Cirrhosis; Simple Noninvasive Index; Soluble St2; Family-Member; Ratio Index; C Patients; Receptor; Models; Fib-4; Identification
dc.titleCan Serum ST2 Levels Be Used as a Marker of Fibrosis in Chronic Hepatitis B Infection?
dc.title.alternativeCan serum ST2 levels be used as a marker of fibrosis in chronic hepatitis B infection?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu